chufangao/CTO huggingface dataset:
Clinical trial NCT04312789: Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant
Official title: A Phase II Trial of Avatrombopag for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplant
Sponsor: Ohio State University Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Drug availability
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-12-31
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT02370238: A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
Official title: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Acronym: FRIDA
Sponsor: Dompé Farmaceutici S.p.A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 194.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-07-29
Primary completion date: 2019-02-20
Completion date: 2020-03-23
Baseline population: The Safety Population consisted of 121 patients who took at least one dose of study treatment
Plan to share individual participant data: NO
Clinical trial NCT03549650: Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Official title: Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms With Prophylactic Pentosan Polysulphate in Patients With Non-Muscle-Invasive Bladder Cancer: A Randomized Controlled Trial
Sponsor: Sir Mortimer B. Davis - Jewish General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Given the updated precautions on Elmiron as well as the risk benefit profile, we have decided to terminate the study.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-03
Primary completion date: 2022-02-15
Completion date: 2022-02-15
Plan to share individual participant data: NO
Clinical trial NCT04099836: Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Official title: Single Arm Phase 2 Trial of Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib (TOP 1901)
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: low accrual
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-07-09
Primary completion date: 2022-11-13
Completion date: 2023-06-15
Plan to share individual participant data: NO
IPD sharing description: There is no plan to share participant level data.
Clinical trial NCT03552380: Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Official title: A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination With Nivolumab Plus Ipilimumab in Patients With Renal Cell Carcinoma Previously Treated With Nivolumab Plus Ipilimumab
Sponsor: Hoosier Cancer Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Funder halted development of compound in this disease
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-07-31
Primary completion date: 2022-06-07
Completion date: 2024-02-15
Plan to share individual participant data: NO
Clinical trial NCT03813199: Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis
Official title: Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Sponsor: Abivax S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-07-04
Primary completion date: 2021-04-27
Completion date: 2021-04-27
Plan to share individual participant data: NO
Clinical trial NCT04736745: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines.
Official title: A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled Dose Escalation and Dose Finding Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines
Acronym: LONG-SET
Sponsor: Ipsen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor terminated the study due to strategic considerations
Enrollment: 56.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-02-10
Primary completion date: 2022-10-28
Completion date: 2022-10-28
Plan to share individual participant data: NO
Clinical trial NCT02874144: Anti-Inflammatory Agent in Sinusitis
Official title: A Phase 2A, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of an Anti-Inflammatory Agent in Patients With Sinusitis
Acronym: E1416
Sponsor: Northwestern University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 43.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-20
Primary completion date: 2020-01-07
Completion date: 2020-08-10
Plan to share individual participant data: NO
Clinical trial NCT03190967: T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Official title: Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: The phase II portion was never started as we could no longer get the drug from the manufacturer.
Enrollment: 12.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-04-18
Primary completion date: 2021-06-28
Completion date: 2023-06-13
Plan to share individual participant data: YES
IPD sharing description: All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP).
IPD time frame: Clinical data are available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol Genomic Data Sharing (GDS) plan for as long as database is active.
IPD access criteria: Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Genomic data are made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.
Clinical trial NCT02954406: A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Official title: A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business decision, insufficient enrollment, no safety or efficacy concerns.
Enrollment: 43.0 (ACTUAL)
Number of arms: 11.0
Start date: 2017-03-05
Primary completion date: 2020-07-27
Completion date: 2020-07-27
Baseline population: Safety Analysis Set included participants who have received at least 1 dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT05119894: A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
Official title: A Multicenter, Open-label, Clinical Pharmacology Trial to Determine the Pharmacokinetics, Tolerability, and Safety of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
Sponsor: Otsuka Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor decision:Change the Development plan
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-11-22
Primary completion date: 2021-12-06
Completion date: 2021-12-06
Plan to share individual participant data: YES
IPD sharing description: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
IPD time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
IPD access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Clinical trial NCT02510976: Prucalopride Versus Placebo in Gastroparesis
Official title: Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying
Sponsor: Universitaire Ziekenhuizen KU Leuven (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Prematurely stopped due to slow recruitment and expiry of study drug.
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-11-30
Primary completion date: 2021-01-08
Completion date: 2021-01-08
Clinical trial NCT05243524: Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer
Official title: Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer.
Acronym: AVALON
Sponsor: ImmunoVaccine Technologies, Inc. (IMV Inc.) (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Closure of IMV operations
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-08-05
Primary completion date: 2023-07-24
Completion date: 2023-08-31
Plan to share individual participant data: NO
Clinical trial NCT02706405: JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Official title: A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Sponsor: Fred Hutchinson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Terminated due to slow accrual.
Enrollment: 30.0 (ACTUAL)
Number of arms: 8.0
Start date: 2016-11-15
Primary completion date: 2021-05-28
Completion date: 2021-05-28
Clinical trial NCT03993379: PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Official title: A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Sponsor: CytomX Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor's Decision
Enrollment: 3.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-11-20
Primary completion date: 2020-05-21
Completion date: 2020-05-21
Baseline population: Due to the early study termination, a statistical analysis plan was not generated. The statistical analyses per the study protocol were not performed due to insufficient sample size and the efficacy and pharmacokinetic analyses were not performed.
Limitations and caveats: Due to developmental strategic reasons and slow enrollment because of the COVID-19 pandemic, the study was terminated early. Three subjects were enrolled, all in Cohort A2. The last subject observation for this study was on 21 May 2020. Since the study terminated early, a statistical analysis plan was not generated.
Plan to share individual participant data: NO
Clinical trial NCT04552795: Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease
Official title: Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease (ART-AD)
Acronym: ART-AD
Sponsor: The University of Texas Health Science Center at San Antonio (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-15
Primary completion date: 2023-05-04
Completion date: 2023-11-04
Plan to share individual participant data: YES
IPD sharing description: Protocol, Published Data
IPD time frame: After study completion, upon publication of data and on ClinicalTrials.gov 1 year after primary completion date of study.
IPD access criteria: Data will be analyzed by the study investigators.
Clinical trial NCT05322616: Single-Ascending Dose Study of JK07 in Subjects With HFpEF
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety and Tolerability of JK07 in Subjects With Heart Failure With Preserved Ejection Fraction (HFpEF)
Sponsor: Salubris Biotherapeutics Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Sponsor decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-21
Primary completion date: 2023-05-26
Completion date: 2023-05-26
Plan to share individual participant data: NO
Clinical trial NCT03298958: Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer
Official title: Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer
Sponsor: The University of Texas Health Science Center at San Antonio (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: No funding was received, no subjects were enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-01
Primary completion date: 2022-02-01
Completion date: 2022-05-01
Plan to share individual participant data: NO
Clinical trial NCT05510427: Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
Official title: Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Per PI's request
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-08-07
Primary completion date: 2023-08-07
Completion date: 2023-08-07
Clinical trial NCT05212818: Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults
Official title: A Phase 2, Multicenter, Randomized, Double-blind (Within Dose), Placebo-controlled, Parallel-group, and Dose-range-finding to Evaluate the Efficacy and Safety in Treatments for COVID-19 in Hospitalized Adults
Sponsor: Techfields Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low patient accrual.
Enrollment: 19.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-05-10
Primary completion date: 2023-02-03
Completion date: 2023-03-08
Plan to share individual participant data: NO
Clinical trial NCT02743546: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Official title: A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of the Combination of Duvortuxizumab With Ibrutinib in Subjects With B-Cell Malignancies
Sponsor: Janssen Research & Development, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2016-07-20
Primary completion date: 2018-09-30
Completion date: 2020-03-31
Clinical trial NCT05028114: Tricaprilin Liquid Formulation PK Study
Official title: A Phase 1, Three-part, Part-randomised, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Different Formulations of Tricaprilin, to Include Single-dose, Food Effect, and Titration Tolerability, in Healthy Participants
Sponsor: Cerecin (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Part 1 was completed, Part 2 and Part 3 of the study were not conducted under this study protocol due to subject recruitment difficulty.
Enrollment: 71.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-08-31
Primary completion date: 2022-03-18
Completion date: 2022-07-19
Plan to share individual participant data: NO
Clinical trial NCT03942601: Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Official title: Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
Acronym: TAP-DANCE
Sponsor: Mercator MedSystems, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Halted due to pandemic.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-01
Primary completion date: 2021-04-30
Completion date: 2021-04-30
Plan to share individual participant data: NO
Clinical trial NCT03166631: A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
Official title: An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Not due to safety reasons.
Enrollment: 62.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-09-08
Primary completion date: 2020-09-15
Completion date: 2020-10-28
Clinical trial NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
Official title: A Randomized, Double-Blind, to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
Sponsor: Alexza Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Administrative decision
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-09-27
Primary completion date: 2024-02-28
Completion date: 2024-02-28
Plan to share individual participant data: NO
Clinical trial NCT04958993: A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer
Official title: A Phase I/II Clinical Study of Anlotinib Hydrochloride Capsule Combined With Concurrent Chemoradiotherapy in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Sponsor: Shandong Cancer Hospital and Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: High incidence of severe radiation pneumonia
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-12
Primary completion date: 2021-11-20
Completion date: 2021-11-22
Clinical trial NCT04282109: Study to Assess the Efficacy and Safety of Nivolumab in Combination with Paclitaxel in Subjects with Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Official title: Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination with Paclitaxel in Subjects with R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Acronym: NIVOTAX
Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 141.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-03
Primary completion date: 2023-09-01
Completion date: 2024-03-21
Clinical trial NCT03561090: A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
Sponsor: Ironwood Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Parallel IW-3718 Phase III trial did not meet pre-specified criteria.
Enrollment: 495.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-20
Primary completion date: 2020-10-07
Completion date: 2020-11-03
Baseline population: Safety Population: randomized participants who received at least 1 dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT04222257: Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis
Official title: Short-course Antibiotic Regimen Compared to Conventional Antibiotic Treatment for Gram-positive Cocci Infective Endocarditis: Randomized Clinical Trial
Acronym: SATIE
Sponsor: Hospital San Carlos, Madrid (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Inability to reach the estimated sample size
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-26
Primary completion date: 2023-03-31
Completion date: 2023-04-01
Clinical trial NCT05262387: A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
Official title: Effectiveness of a Basal Rate Reduction With LyumjevTM Versus Humalog® on the Protection From Exercise-Induced Hypoglycemia in Individuals With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-02-14
Primary completion date: 2023-03-07
Completion date: 2023-03-07
Baseline population: All participants who received at least one dose of study drug.
Plan to share individual participant data: NO
Clinical trial NCT02561117: Once Daily Metronidazole for Perforated Appendicitis
Official title: Metronidazole Every 24 Hours as Part of Triple Antibiotic Therapy for Ruptured Appendicitis in Children Managed Operatively (METRO): a Noninferiority Randomized Controlled Trial
Acronym: METRO
Sponsor: Children's Hospital of Eastern Ontario (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-01-31
Primary completion date: 2021-01-31
Completion date: 2022-01-31